Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. BRINEURA (cerliponase alfa)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

BRINEURA (cerliponase alfa)

Medicine - Posted on Dec 12 2024
Active substance (DCI)
  • cerliponase alfa
history (2)
  • 11/27/24

    BRINEURA 150 mg (cerliponase alfa) - ) Rare disease

    Summary of opinion Favourable opinion for maintenance of reimbursement in “the treatment of neuronal ceroid lipofuscinosis t...
    CAV :
    54321
    icône flèche
  • 6/20/18

    BRINEURA (cerliponase alfa), simple class

    High clinical benefit for neuronal ceroid lipofuscinosis type 2 and moderate clinical added value in the management of this ...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • A16AB17
Manufacturer
BIOMARIN INTERNATIONAL LIMITED
Presentation

BRINEURA 150 mg, solution pour perfusion (code CIS : 65808346)
2 flacon(s) en verre de 5 ml - 1 flacon(s) en verre de 5 ml (CIP : 34009 550 337 1 4)

All our publications
    Congenital, genetic and rare diseases Drug therapy Metabolic diseases Neurodegenerative diseases Paediatrics

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
1ZqrMn08WN9R26kt